Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.

Nicholas J, Boster A, Wu N, Yeh WS, Fay M, Kendter J, Huang MY, Lee A.

Pharmacoecon Open. 2018 Mar;2(1):31-41. doi: 10.1007/s41669-017-0035-2.

2.

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.

Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M, Huang MY, Lee A.

Neurol Ther. 2017 Jun;6(1):91-102. doi: 10.1007/s40120-017-0064-x. Epub 2017 Feb 16.

3.

Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.

Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P, Boster AL.

Neuromodulation. 2016 Aug;19(6):632-41. doi: 10.1111/ner.12467. Epub 2016 Jul 19. Review.

PMID:
27434299
4.

Best Practices for Intrathecal Baclofen Therapy: Patient Selection.

Saulino M, Ivanhoe CB, McGuire JR, Ridley B, Shilt JS, Boster AL.

Neuromodulation. 2016 Aug;19(6):607-15. doi: 10.1111/ner.12447. Epub 2016 Jul 19. Review.

PMID:
27434197
5.

Best Practices for Intrathecal Baclofen Therapy: Screening Test.

Boster AL, Bennett SE, Bilsky GS, Gudesblatt M, Koelbel SF, McManus M, Saulino M.

Neuromodulation. 2016 Aug;19(6):616-22. doi: 10.1111/ner.12437. Epub 2016 Jul 19. Review.

PMID:
27434115
6.

Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management.

Boster AL, Adair RL, Gooch JL, Nelson ME, Toomer A, Urquidez J, Saulino M.

Neuromodulation. 2016 Aug;19(6):623-31. doi: 10.1111/ner.12388. Epub 2016 Jul 19. Review.

PMID:
27433993
7.

Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control.

Schmalbrock P, Prakash RS, Schirda B, Janssen A, Yang GK, Russell M, Knopp MV, Boster A, Nicholas JA, Racke M, Pitt D.

AJNR Am J Neuroradiol. 2016 Mar;37(3):439-46. doi: 10.3174/ajnr.A4599. Epub 2015 Nov 26.

8.

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y.

Expert Rev Neurother. 2015 Jun;15(6):575-86. doi: 10.1586/14737175.2015.1040768. Epub 2015 Apr 30. Review.

PMID:
25924547
9.

The effects of video-game training on broad cognitive transfer in multiple sclerosis: A pilot randomized controlled trial.

Janssen A, Boster A, Lee H, Patterson B, Prakash RS.

J Clin Exp Neuropsychol. 2015;37(3):285-302. doi: 10.1080/13803395.2015.1009366. Epub 2015 Apr 7.

PMID:
25850024
10.

Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration.

Orack JC, Deleidi M, Pitt D, Mahajan K, Nicholas JA, Boster AL, Racke MK, Comabella M, Watanabe F, Imitola J.

Stem Cells Transl Med. 2015 Mar;4(3):252-60. doi: 10.5966/sctm.2014-0133. Epub 2015 Jan 15. Review.

11.

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Nicholas JA, Boster AL, Imitola J, O'Connell C, Racke MK.

Drug Des Devel Ther. 2014 Jul 7;8:897-908. doi: 10.2147/DDDT.S50962. eCollection 2014. Review.

12.

Managing loss of intrathecal baclofen efficacy: Review of the literature and proposed troubleshooting algorithm.

Boster A, Nicholas J, Bartoszek MP, O'Connell C, Oluigbo C.

Neurol Clin Pract. 2014 Apr;4(2):123-130.

13.

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21.

14.

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

Nicholas JA, Racke MK, Imitola J, Boster AL.

Ther Adv Chronic Dis. 2014 Mar;5(2):62-8. doi: 10.1177/2040622313514790. Review.

15.

Multiple sclerosis: Five new things.

Nicholas JA, Boster AL, Racke MK.

Neurol Clin Pract. 2013 Oct;3(5):404-412. Erratum in: Neurol Clin Pract. 2014 Feb;4(1):4.

16.

Resting-state functional connectivity in multiple sclerosis: an examination of group differences and individual differences.

Janssen AL, Boster A, Patterson BA, Abduljalil A, Prakash RS.

Neuropsychologia. 2013 Nov;51(13):2918-29. doi: 10.1016/j.neuropsychologia.2013.08.010. Epub 2013 Aug 20.

PMID:
23973635
17.

Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.

Mehta V, Pei W, Yang G, Li S, Swamy E, Boster A, Schmalbrock P, Pitt D.

PLoS One. 2013;8(3):e57573. doi: 10.1371/journal.pone.0057573. Epub 2013 Mar 14.

18.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
19.

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A.

J Cent Nerv Syst Dis. 2012 May 16;4:81-103. doi: 10.4137/JCNSD.S6692. Print 2012.

20.

Physical activity associated with increased resting-state functional connectivity in multiple sclerosis.

Prakash RS, Patterson B, Janssen A, Abduljalil A, Boster A.

J Int Neuropsychol Soc. 2011 Nov;17(6):986-97. doi: 10.1017/S1355617711001093.

PMID:
22040897
21.

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M.

Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.

22.

The potential role of B cell-targeted therapies in multiple sclerosis.

Boster A, Ankeny DP, Racke MK.

Drugs. 2010 Dec 24;70(18):2343-56. doi: 10.2165/11585230-000000000-00000. Review.

PMID:
21142258
23.

Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging.

Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, Rammohan K, Knopp MV, Schmalbrock P.

Arch Neurol. 2010 Jul;67(7):812-8. doi: 10.1001/archneurol.2010.148.

PMID:
20625086
24.

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

Khan OA, Tselis A, Boster A.

Neurology. 2009 Jun 16;72(24):2134; author reply 2134-5. doi: 10.1212/01.wnl.0000349656.65459.5f. No abstract available.

PMID:
19528523
25.

Pharmacotherapy of multiple sclerosis: the PROOF trial.

Boster A, Racke MK.

Expert Opin Pharmacother. 2009 Jun;10(8):1235-7. doi: 10.1517/14656560902927856.

PMID:
19463066
26.

Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.

Boster A, Hreha S, Berger JR, Bao F, Penmesta R, Tselis A, Endress C, Zak I, Perumal J, Caon C, Vazquez J, Tyler KL, Racke MK, Millis S, Khan O.

Arch Neurol. 2009 May;66(5):593-9. doi: 10.1001/archneurol.2009.31.

PMID:
19433659
27.

Pediatric-onset multiple sclerosis in African-American black and European-origin white patients.

Boster AL, Endress CF, Hreha SA, Caon C, Perumal JS, Khan OA.

Pediatr Neurol. 2009 Jan;40(1):31-3. doi: 10.1016/j.pediatrneurol.2008.09.004.

PMID:
19068251
28.

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O.

Drugs. 2008;68(17):2445-68. doi: 10.2165/0003495-200868170-00004. Review.

PMID:
19016573
29.

Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence.

Boster A, Caon C, Perumal J, Hreha S, Zabad R, Zak I, Tselis A, Lisak R, Khan O.

Mult Scler. 2008 Jul;14(6):804-8. doi: 10.1177/1352458507088156. Epub 2008 Jun 23.

PMID:
18573830
30.

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O; Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine.

Lancet Neurol. 2008 Feb;7(2):173-83. doi: 10.1016/S1474-4422(08)70020-6. Review.

PMID:
18207115

Supplemental Content

Loading ...
Support Center